Tocilizumab reduces hypercoagulation in COVID-19 – Perspectives from the coagulation and immunomodulation Covid assessment (Coag-ImmCovA) clinical trial
Tocilizumab treatment demonstrated a significant reduction of hypercoagulation in hospitalized COVID-19 patients, by improvements in both global coagulation tests and conventional laboratory tests, in comparison with anakinra or SC alone. This finding underscores the significance of tocilizumab as a viable treatment option in severe COVID-19 cases, with the potential to decrease thrombosis incidence.
Authors
- Apostolos Taxiarchis (ORCID: https://orcid.org/0000-0003-2137-715X)
- Carl‐Magnus Wahlgren (ORCID: https://orcid.org/0000-0002-9619-3577)
- Michael Wanecek
- Jan van der Linden (ORCID: https://orcid.org/0000-0003-4502-6282)
- Lou M. Almskog (ORCID: https://orcid.org/0000-0002-5576-5129)
- Jonas Sundén‐Cullberg (ORCID: https://orcid.org/0000-0002-8189-4960)
- Agneta Wikman (ORCID: https://orcid.org/0000-0002-8810-7974)
- Jon Lampa (ORCID: https://orcid.org/0000-0002-7856-3968)
- Maria Magnusson (ORCID: https://orcid.org/0000-0001-5388-6608)
- Sara Freyland
- Anna Ågren (ORCID: https://orcid.org/0000-0002-7403-4305)
- Anna Sjöström (ORCID: https://orcid.org/0000-0002-9659-344X)
- Jovan P. Antović (ORCID: https://orcid.org/0000-0002-9860-1108)
- Madeleine Börjesson
Institutions
- Karolinska University Hospital (SE)
- Karolinska Institutet (SE)
- Saint Göran Hospital (SE)
- St Göran's Children's Hospital (SE)
Publication Details
- Journal
- Thrombosis Research
- Published
- 2024-08-30
- DOI
- https://doi.org/10.1016/j.thromres.2024.109135
- Citations
- 3
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.17
Funders
- Vetenskapsrådet